BioOutsource To Open New Biosimilar Centre of Excellence in Glasgow as Global Demand Surges
GLASGOW, UNITED KINGDOM - Feb 5, 2014 - BioOutsource Ltd.
("BioOutsource"), a global leader in biologics contract testing and
biosimilar characterization for the biopharmaceutical industry,
today announced the opening of a new Biosimilar Centre of
Excellence in Glasgow. The new facility will double the company's
capacity for the analysis of biosimilar
monoclonal antibodies.
"The global biosimilar market is predicted to more than double in
size to $19 billion by 2018. The increasing demand for our
biosimilars services and the addition of several new clients has
made this a necessary investment for 2014, as our revenues in this
market have quadrupled in the last 18 months," commented
BioOutsource CEO, Gerry MacKay. "We are delighted to announce the
opening of this new, state-of-the-art Biosimilar Centre of
Excellence in Glasgow."
The Biosimilar Centre of Excellence is located on the West of
Scotland Science Park in Glasgow, adjacent to the existing
BioOutsource facility. The new operation will consist of
approximately 40 laboratory and R&D scientists creating an
estimated 20 new jobs.
"We are committed to providing our clients with excellent levels of
service and technical support" continued Mr. MacKay. "In 2013 we
increased our headcount by 30% as we added new services to our
portfolio and we anticipate repeating this expansion in the first
quarter of this year. We have now worked with no fewer than 30
global biosimilar companies who use our range of off-the-shelf
assays for the comparability, stability and lot release testing of
their biosimilars."
Mr. MacKay concluded, "Importantly, we feel that our growth in this
fast emerging market is driven by our extensive investments in an
R&D program, which is developed and refined in conjunction with
all our global clients."
About
BioOutsource Ltd.
BioOutsource provides contract testing services to the
biopharmaceutical industry. Our core offering includes a
comprehensive range of services to support the testing of
Biologics, Vaccines & Biosimilars throughout their development.
We possess an unparalleled combination of commercial, regulatory
and technical knowledge that enables us to truly stand out as the
industry's increasingly preferred testing partner. We understand
the importance of our service to support our client's critical
testing requirements and as a result, continually strive to provide
a world class service globally.
Contacts
Gemma Fulton, Sales & Marketing Associate, BioOutsource Ltd.
gfulton@biooutsource.com